ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / VRXA / financials
PDSB (45) CNTN (37) CUE (33) NGEN (49) ⌘ Pro Terminal →

Veraxa Biotech AG (VRXA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.14 +0.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.14

Veraxa Biotech AG (VRXA) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY) →
ROARABLE C- • HOLD / WATCH Cap $159.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VRXA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VRXA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Veraxa Biotech AG (NASDAQ: VRXA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $1.14 (+0.89% 1D, market cap $159.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VRXA ranks #177 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VRXA compare to PDSB and CNTN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRXA carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PDSB (PDS Biotechnology Corporation) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $162.8M) and CNTN (Canton Strategic Holdings Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -4.1%, cap $163.3M). Among the 5-stock peer group, VRXA leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VRXA?
▼

For Veraxa Biotech AG (VRXA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #177 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.14 (-0.03%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510060
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Cash (12)Whales (13)SEC (13)Macro (13)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+0.9% Base Target
$29 Bull$1 Base$1 Bear
📬 FREE VRXA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VRXA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (60/100 Composite)
🔍 WHY VRXA SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (22% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
68
Grade B-$1.26-11.9% Next Q
Q2 (-2Q)
65
Grade C+$1.11-9.9% Next Q
Q3 (-1Q)
63
Grade C+$1.00+14% Next Q
Current
60
Grade C-$1.14+0.4% Hist 90D α
Trajectory: B- (68) → C- (60)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VRXA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 60/100 (C-) score, VRXA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.33) or 200D SMA ($6.97) invalidates the momentum regime and cuts Target Base ($1.15) toward Bear Floor ($0.90).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VRXA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VRXA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 60%NO 40%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How VRXA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$4.5M (0.1% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VRXA)

  • ✓Walkthrough of VRXA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VRXA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.09%⚡ TESTING RESISTANCE
2026-10-30O $1.15H $1.25L $1.08C $1.14VOL 261.4K
RES: $1.15SUP: $0.89SMA50: $1.33SMA200: $6.97
$29.21$21.55$13.89$6.23$-1.43RES $1.15SUP $0.89$1.142026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VRXA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VRXA Butterfly Map → + Track VRXA →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VRXA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VRXA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VRXA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VRXA)

Health Care Rank #177 of 1016 ⚔️ PDSB vs VRXA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VRXA vs. PDSB, CNTN, CUE, NGEN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Veraxa Biotech AG (VRXA) ranks #177 by composite RQD confidence (60/100, grade C-) and #603 by equity capitalization ($159.8M). Within this direct 5-issuer industry benchmark cohort, VRXA leads on earnings valuation at N/A trailing P/E, while CNTN leads on capital efficiency and profitability with -4.1% ROIC and — gross margin. VRXA currently leads its immediate peer cohort in composite quantitative strength at 60/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VRXA ACTIVE
Veraxa Biotech AG
C- 60/100 — — — +0.89% $159.8M Benchmark Subject
PDSB
PDS Biotechnology Corporation
D 45/100 — — -35.0% -7.10% $162.8M /pdsb-vs-vrxa →
CNTN
Canton Strategic Holdings Inc.
D- 37/100 — — -4.1% -4.88% $163.3M /cntn-vs-vrxa →
CUE
Cue Biopharma Inc.
E 33/100 — — -35.0% -2.70% $155.8M /cue-vs-vrxa →
NGEN
NervGen Pharma Corp.
D 49/100 — — — -4.86% $155.0M /ngen-vs-vrxa →

2. VRXA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Veraxa Biotech AG (VRXA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $159.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. VRXA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VRXA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Veraxa Biotech AG (NASDAQ: VRXA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $1.14 (+0.89% 1D, market cap $159.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VRXA ranks #177 in composite RQD confidence.

How does VRXA compare to PDSB and CNTN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRXA carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PDSB (PDS Biotechnology Corporation) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $162.8M) and CNTN (Canton Strategic Holdings Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -4.1%, cap $163.3M). Among the 5-stock peer group, VRXA leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VRXA?

For Veraxa Biotech AG (VRXA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #177 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VRXA trading relative to its 50-day, 200-day, and 52-week technical levels?

VRXA last traded at $1.14 (+0.89% on volume of 261,438 shares), positioning the stock -14.29% below its 50-day simple moving average ($1.33) and -83.64% below its 200-day simple moving average ($6.97). Across its 52-week range of $0.95 to $27.36, VRXA sits at the 0.7% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.28).

VRXA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Veraxa Biotech AG (VRXA)?

In Trailing 12 Months, VRXA converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $4.5M in free cash flow (0.1% FCF margin).

Direct Sub-Reports: VRXA RQD Cockpit VRXA 12M Forecast VRXA Earnings & Move VRXA Dividends & DRIP VRXA Insiders & 13F VRXA Whale Options VRXA Profit Sankey VRXA News & Why
ROARABLE RATING BRIEF • RQD 60/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

VRXA — Veraxa Biotech AG: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:17:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, VRXA scores 60 out of 100, a letter grade of C-, with a verdict label of "Roarable Hold — Cautious Neutral." The Fundamental Cash Engine pillar scores 12 of 20, reflecting an ROIC of 0% and an FCF yield of 0%; for a prospective investor, this means the rating system sees no current return on invested capital and no free-cash yield to support the share price. The Whale/13F Flow pillar scores 13 of 20 on institutional accumulation and options positioning, indicating some modest institutional support, though the underlying holder detail is not itemized in the source data. The Insider Conviction pillar scores 9 of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest pillar in the set, which signals weaker insider-driven confidence signals. The Macro Regime Fit pillar scores 13 of 20 with a beta of 1.0 and a sector sensitivity assessment, suggesting market-level volatility exposure roughly in line with the broad market. The Forensic Balance Sheet pillar scores 13 of 20 using an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5, which is the strongest relative pillar and points to a balance sheet that is neither distressed nor strong. Taken together, the upside case rests on institutional interest, a moderate balance sheet, and recent clinical-stage news flow, while the valuation tradeoff is that the company currently shows no reported profitability, no free cash generation, and a share price that has traded between $0.95 and $27.36 over the past 52 weeks, so the rating reflects caution rather than conviction.

Business

Veraxa Biotech AG (VRXA) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is publicly traded with a market capitalization of $0.2B. The source data does not describe its products, customers, or revenue model in detail. Recent news references a BiTAC-ADC platform and FDA-aligned testing methods, which are described in the catalysts section below.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. For a prospective investor, the absence of mapped links means ripple effects from suppliers, partners, or customers cannot be assessed from this dataset.

Open Questions

  • What are the company's reported revenue, operating income, net income, and cash balances across recent periods?
  • What is the timing, scope, and outcome of the BiTAC-ADC clinical program referenced in the news?
  • Who are the institutional 13F holders, and what are the sizes and direction of their positions?
  • What is the terms and the context of the director share purchases relative to the de-SPAC transaction?
  • What is the company's cash runway and debt maturity profile underlying the reported Debt/Equity of 0.5?

VRXA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Veraxa Biotech AG (VRXA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VRXA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VRXA Bull vs. Bear Conversation Board — What's Your Call at $1.14?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VRXA 🐻 50% BEARISH CONVICTION
1. Pick Your Side on VRXA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.23 (+7.9%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is VRXA (C- • RQD 60/100) a Buy at $1.14?

Welcome to the VRXA (Veraxa Biotech AG) Roar Pit. Current RQD Composite is 60/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.90 (-21.1%)
Spot @ $1.14

Pump the brakes on VRXA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on VRXA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Veraxa Biotech AG expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.30 (+14.0%)
Spot @ $1.14

VRXA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on VRXA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.14 (52-wk range $0.95 - $27.36), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%